Characterization of Cephalosporinases Produced by Clinical Isolates of Enterobacteriacae in North Lebanon by Bayssari, Charbel Al et al.
iMedPub Journals
Our Site: http://www.imedpub.com/
© Under License of Creative Commons Attribution 3.0 License 1
2013
Vol. 3 No. 2:2
doi: 10.3823/729
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
Characterization of 
Cephalosporinases 
Produced by 
Clinical Isolates of 
Enterobacteriacae 
in North Lebanon
1  Medical Microbiology 
Laboratory, Azm Center for 
Research in Biotechnology 
and Its Applications, 
Doctoral School of Sciences 
and Technology, Lebanese 
University, Tripoli, Lebanon 
2  Faculty of Public Health, 
Lebanese University, Tripoli, 
Lebanon
3  Clinical Laboratory, Nini 
Hospital, Tripoli, Lebanon.
4  Bacteriology-Hygiene 
Service, University Hospital 
of Amiens, North Hospital, 
80054 Amiens, France,
Correspondence: 
 mhamze@ul.edu.lb/ 
mhamze@monzerhamze.com
*  Prof. Monzer Hamze, 
Health and Environment 
Microbiology laboratory, 
Azm Center for Research 
in Biotechnology, Doctoral 
School of Sciences and 
Technology, Lebanese 
University, Tripoli, Lebanon. 
Tel.: +961 (6) 213 252
Mob: +961 (3) 228 881
fax:  +961 (6) 213 383. Tripoli, 
Lebanon.
Charbel Al Bayssari1, Monzer Hamze1,2*, Hassan Mallat2, 
Marcel Achkar3, Hedi Mammeri4 and Fouad Dabboussi1,2.
This article is available from: 
www.iajaa.org
Abstract
Background: The problem of Enterobacteriacae resistance to β-Lactamase drugs 
is of growing concern in hospitals. Enterobacteria have developed multiple mecha-
nisms of resistance to antibiotics, the main one is the enzymatic resistance medi-
ated by the beta-lactamases. This study aims to characterize the occurrence of 
cephalosporinases in clinical isolates of Enterobacteriacae isolates in North Lebanon. 
Methods. Twenty two strains of Enterobacteriacae producing high level of cepha-
losporinases have been studied. The antibiotic susceptibility of each strain was 
tested on Mueller Hinton agar contains cloxacilline (250 mg/L) and by using E-test 
according the guidelines of the Antibiogram Committee of the French Society for 
Microbiology. The search for plasmid-mediated cephalosporinases was performed 
using PCR and primers for plasmid-mediated cephalosporinases genes (CMY-2, 
DHA-1, ACT-1, ACC-1, FOX-1 and MOX-1). 
Results: Thirteen positive strains were detected, of these 9 strains produced the 
plasmid-mediated cephalosporinase (CMY-2) and one strain produced the plasmid-
mediated cephalosporinase (DHA-1). The remaining 9 strains were high-level chro-
mosomal cephalosporinase producers since they belong to group-three Enterobac-
teria. They did neither produce plasmid-mediated cephalosporinase, nor did they 
have resistance to third generation cephalosporins except for cefepim. Two strains 
(CMUL E. coli 021) and CMUL E. coli 255) which were not susceptible for cefepim by 
E-test produced plasmid-mediated cephalosporinase The sequencing result of these 
2 E.coli strains did not show any mutation in the promoter that is responsible for 
high expression level of the chromosomal cephalosporinase. All examined strains 
producing plasmid-mediated cephalosporinase CMY-2 were analyzed by ERIC-PCR 
technique. The results showed that two of these strains had the same pattern (C4 
and C5) and three others had another pattern (C10, C12 and C13). 
Conclusion: This study shows the variations of cephalosporinases produced by 
clinical isolates of Enterobacteriacae in North Lebanon.
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Introduction
The evolution of extended-spectrum β-lactamases (ESBLs), 
particularly CTX-M with high levels of resistance to third 
generation cephalosporins have been increased recently in 
Enterobacteriacae strains mediated via a plasmidic class of 
cephalosporinase [1]. Class C beta-lactamases (AmpC) is a 
group of enzymes widely distributed among enterobacteria. 
They preferentially inactivate narrow spectrum cephalospo-
rins and, in a lesser extent they inactivate the broad-spectrum 
cephalosporins such as ceftazidime and cefotaxime. How-
ever, cefepim is a poor substrate for AmpC in vitro, and it 
remains active against isolates of enterobacteria that hyper 
producer of AmpC. Plasmidic cephalosporinase that derived 
from chromosomal AmpC of different Gram-negative bac-
teria has emerged since the 1980s. These plasmid-mediated 
enzymes can be divided into five or six clusters; the C. freundii 
group with LAT types and certain CMY types, the Entero-
bacter group with MIR-1 and ACT-1, the M. morganii group 
with DHA-1 and DHA-2, the H. alvei group represented by 
ACC-1, and the Aeromonas group with MOX-1, FOX-1 and 
other CMY-type enzymes [2]. AmpC enzymes typically have 
molecular masses of 34 to 40 kDa and isoelectric points of 
8.0, although the isoelectric points of plasmid-mediated FOX 
enzymes are lower (6.7 to 7.2) [2], and the isoelectric point 
of an AmpC enzyme of Morganella morganiiis equal to 6.6 
[3]. These enzymes are located in the bacterial periplasmic 
cell part with the exception of the AmpC β-lactamase of the 
Psychrobacter immobilis, which is secreted mainly into the 
external medium [4]. They are poorly inhibited by p-chloro-
mercuribenzoate and not inhibited at all by EDTA. Cloxacil-
lin, oxacillin, and aztreonam, however, are good inhibitors 
[5]. The resistance phenotype of a high level chromosomal 
cephalosporinase-producing strain is similar to that producing 
a plasmidic AmpC. There is resistance to first, second and 
even to third generation cephalosporins, but its susceptible to 
the fourth generation like cefepim. A striking feature of this 
development is the global distribution of the strains produc-
ing plasmid-determined cephalosporinases. These have been 
found in Africa (Algeria, Tunisia), Asia (India, Japan, Pakistan, 
South Korea), Europe (France, Germany, Greece, Italy, Swe-
den, United Kingdom), the Middle East (Saudi Arabia), North 
America (United States), and South and Central America (Ar-
gentina, Guatemala) [2]. 
The aim of our study is to characterize the cephalosporinases 
in twenty two clinical isolates of Enterobacteriacae at Nini 
hospital in North Lebanon.
Materials and Methods
Clinical isolates
Twenty-two clinical isolates of Enterobacteriacae producing 
cephalosporinases were obtained from the microbiological 
laboratory of Nini hospital- North Lebanon. These were iso-
lated between 2009 and 2012 and kept at -80ºC in the mi-
crobiological department of Azm center. The isolates were 
obtained from a range of clinical specimens. The most com-
mon origin of theses isolates was urine (43%), followed by 
tracheal aspirations (24.42%), wound (10.86%), perineum, 
stools (5.43%). All isolates were initially identified with the API 
20 E system (biomérieux, Marcy l’Etoile, France) or RapIDone 
system (Remel, USA), then by the use of mass spectrometry 
technique (Bruker Daltonik MALDI Biotyper). Susceptibility of 
the strains was tested using the diffusion disc method [6] and 
Mueller Hinton agar (Bio-Rad – France) containing cloxacilline 
(250 mg/L) to check the inhibition of cephalosporinase by 
cloxacillin according to the recommendations of the Antibio-
gramm Committee of the French Society for Microbiology 
(CA-SFM) [7]. The following antibiotics discs (Bio-Rad-France) 
were tested: Ampicillin (AM) 10 μg, Ticarcillin (TIC) 75 μg, 
Piperacillin (PIP) 30 μg, Cefoxitin (FOX) 30 μg, Cefotaxime 
(CTX) 30 μg, Amoxicillin / Clavulanic acid (AMC) 20 μg/10 μg, 
Ceftazidime (CAZ) 30 μg, Colistin (CS) 50 μg, Ofloxacin (OFX) 
5 μg, Piperacillin/Tazobactam (TZP) 75 μg, Trimethroprim/Sul-
fametoxazole (SXT) 1.25 μg/32.75 μg, Gentamycin (GM) 10 
μg, Tobramycin (TM) 10 μg, Netilmicin (NET) 30 μg, Ami-
kacin (AN) 30 μg, Cefepime (FEP) 30 μg, Azrteonam (ATM) 
30 μg, Tigecycline (TGC) 15 μg, Moxalactam (MOX) 30 μg, 
Ertapenem (ETP) 10 μg, Imipenem (IPM) 10 μg and Ticarcillin/
Clavulanic Acid (TCC) 75 μg/10 μg. The minimum inhibitory 
concentration against the following drugs: Cefepime, cefo-
taxime, ceftazidime and ertapenem, was determined using 
E-test system on Mueller Hinton agar (Bio-Rad). Breakpoints 
were interpreted according to the CA-SFM [7]. The strains of 
E. coli or those that belong to group-3 enterobacteria which 
showed resistance to cefepime were analyzed and a sequenc-
ing of their AmpC coding gene was performed for potential 
detection of ESAC (extended spectrum AmpC).
Bacterial DNA extraction
The DNAs of all Enterobacteriacae isolates were extracted 
automatically using the automate NucliSENS easyMAG ac-
cording to the manufacturer’s instructions and they were 
stored at - 18º C.
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PCR of extracted DNA
The extracted DNAs were used as templates to amplify plas-
mid born AmpC genes (DHA-1, CMY-2, ACT-1, ACC-1, FOX-1 
and MOX-1) under the following PCR conditions: denatur-
ation for 5 min at 94ºC; 35 cycles of 1 min at 94ºC, 1 min 
at 55ºC and 1 min at 72ºC; and a final extension step of 10 
min at 72ºC [8, 9]. The set of primers, which were used to 
amplify the bla-AmpC genes are presented in table 1. Posi-
tive control strains used are listed in table 2.
Primers AmpC HN-F and AmpC B2-R were used to amplify 
the chromosomal AmpC gene under the following PCR con-
ditions: denaturationby 1 cycle of 5 min at 94ºC; 30 cycles 
of 1 min at 94ºC, 1 min at 55ºC and 2 min at 72ºC; and a 
final extension step of 10 min at 72ºC. 
Table 1. Primers used for plasmid-mediated AmpC gene amplification and the sequencing primers used in this study.
Primers Sequence (5’→ 3’) Reference
AmpC HN – F
AmpC B2 - R
AAAAGCGGAGAAAAGGTCCG
TTCCTGATGATCGTTCTGCC 8
CIT MF
CIT MR
TGGCCAGAACTGACAGGCAAA
TTTCTCCTGAACGTGGCTGGC 9
DHA-1-A (F)
DHA-1-B (R)
ATGAAAAAATCGTTATCTGC
TTATTCCAGTGCACTCAAAATAGC 8
ACT-1-A (F)
ACT-1-B (R)
GGATGAGGTCAAGGATAACG
GGTGGATTCACTTCTCTCGC 12
ACC-1-A (F)
ACC-1-B (R)
ATGCAGAACACATTGAAGC
CTACTTATTCCCTTCCAATGAGC 8
FOX1-1-A (F)
FOX1-1-B (R)
ATGAATGCCAATTTCATTCACC
TCACTCGGCCAACTGACTCAGG 8
MOXMF
MOXMR
GCTGCTCAAGGAGCACAGGAT
CACATTGACATAGGTGTGGTGC 9
ERIC2 AAGTAAGTGACTGGGGTGAGCG 10
Table 2. Positive control strains used in this study.
Strains Gene Reference
E. coli TOP10 (pCMY-2) CMY-2 8
E. coli TOP10 (pACT-1) ACT-1 8
E. coli TOP10 (pFOX-1) FOX-1 8
E. coli TOP10 (pDHA-1) DHA-1 8
E. coli TOP10 (pACC-1) ACC-1 8
E. coli JM101 (pLRB01) MOX-1 11
PCR amplification was performed in a 50 μL mixture contain-
ing 5 μL of 10X buffer (Sigma-Aldrich, St Louis, MO, USA), 
3μL of MgCl2, 8 μL of mix deoxynucleotide triphosphates 
(dNTPs; Sigma Aldrich), 0.2 μL of Taq Polymerase (Sigma Al-
drich), 2.5 μL of each primer and 2 μL of the DNA template 
[8, 9]. Amplification of the target regions was performed in 
a thermal cycler (Veriti thermal cycler, Applied Biosystems), 
then a migration on gel electrophoresis was performed, and 
the sizes of plasmid-mediated AmpC genes were revealed by 
the molecular weight marker (Smart Ladder). 
Sequencing of chromosomal AmpC gene
The PCR products obtained by using the primers of the chro-
mosomal AmpC gene (AmpC HN-F and AmpC B2-R) were 
used for sequencing. Before sequencing, the PCR products 
have undergone purification using the purification kit Qia-
gen QiaQuick according to the manufacturer’s instructions. 
Following the purification, the sequencing of the chromo-
somal AmpC gene was performed using the sequencing kit 
Coffet Big Dye terminator cycle sequencing kit (Applied Bio-
systems®). For each PCR product, two sequencing reactions 
were performed, in each sample one type of primer was 
used (forward and reverse), with a total volume of 20 μL. 
Each reaction contained 4 μL of MixRR (Sigma Aldrich), 2 
μL of Buffer 5X, 7μL of purified water, 3 μL of purified PCR 
product and 4 μL of primer 1 μM (the forward primer in 
a reaction and the reverse primer in the second), then the 
thermalcycle (Veritithermacycler, Applied Biosystems®) was 
run for 30 cycles consisting of initial heat activation at 96ºC 
for 3 min, denaturation at 96ºC for 30s, annealing at 55ºC 
iMedPub Journals
Our Site: http://www.imedpub.com/
4 © Under License of Creative Commons Attribution 3.0 License
2013
Vol. 3 No. 2:2
doi: 10.3823/729
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
for 15s and elongation at 60ºC for 4 min, with a final step 
at 10ºC for 7 min. After the sequencing, purification was 
performed using the kit Qiagen DyeEx spin kit according to 
the manufacturer’s instructions (Applied Biosystems®), fol-
lowed by a spectral analysis with genetic analyzer ABI3100.
Molecular typing
All strains that produced the same type of plasmid-mediated 
AmpC were typed using the ERIC-PCR technique (Enterobac-
terial repetitive Intergenic consensus) as described previously 
[13, 14]. The primer used in this typing technique is listed in 
table 1.
Results
Among the twenty two strains studied, nine strains produced 
high level chromosomal AmpC, followed by 12 strains pro-
duced the plasmid-mediated AmpC CMY-2 and one strain 
produced the plasmid-mediated AmpC DHA-1. There were 
no strains producing one of the following plasmid-mediated 
AmpC: ACT-1, ACC-1, FOX-1 or MOX-1. The result of suscep-
tibility testing against different antimicrobial agents is shown 
in table 3.
Table 3.  Mean of antibiotic susceptibility patterns of Entero-
bacteriacae strains against different antibiotics.
Antibiotics % S % R % I
AM 0 100 0
TIC 0 100 0
PIP 0 100 0
AMC 0 100 0
TCC 0 100 0
CF 0 100 0
FOX 0 100 0
CTX 4.5 86 9.5
CAZ 4.5 91 4.5
FEP 86.5 13.5 0
CS 100 0 0
OFX 41 50 9
TZP 45.5 9 45.5
SXT 41 59 0
GM 72.7 27.3 0
TM 59 36.5 4.5
NET 77.3 13.7 9
AN 100 0 0
ATM 4.5 45.5 50
TGC 77.3 0 22.7
MOX 50 50 0
ETP 59 18 23
IPM 95.5 0 4.5
S:  Susceptible I: Intermediate, R: Resistant. MICs of all 
Enterobacteriacae isolates strains against cefotaxime, 
ceftazidime, cefepime and ertapenem are shown in table 4. 
All strains of E. coli which belong to enterobacteria group-3 
and which showed resistance to cefepime through the use of 
E-test, were analyzed and a sequencing of their AmpC gene 
was performed for potential detection of ESAC. These strains 
were CMUL E. coli 021 and CMUL E. coli 255. The result of 
their AmpC gene is shown in figure 1. There wasn’t any 
mutation at the promoter in the -35 and -10 boxes,neither 
was there a mutation at position -42 (C to T substitution) 
that are normally responsible for the appearance of a strong 
promoter at the origin of the high level expression of E. coli 
chromosomal AmpC. The twelve strains that produced the 
plasmidic AmpC CMY-2 were analyzed by the ERIC-PCR 
technique (fig. 2). The twelve isolates showed nine distinct 
fingerprints. Enterobacteria group-1 included the following 
strains with identical patterns (C10: CMUL E. coli 224, C12: 
CMULE. coli 257 and C13: CMULE. coli 256was the largest 
group). Group-2 comprised two strains with similar patterns 
(C4: CMUL E. coli 226 and C9: CMUL E. coli 225). As for the 
remainder of the isolates, each produced unique patterns 
(C2: CMUL E. coli 258, C3: CMUL E. coli 255, C5: CMUL E. 
coli 021, C6: CMUL E. coli 245, C14: CMUL E. coli 243, C16: 
CMUL E. coli 250 and C18: CMUL E. coli 241)
Discussion
To our best knowledge, this is the first study in Lebanon, 
which describes characterization of cephalosporinases pro-
duced by clinical isolates of Enterobacteriacae.
The results of our study showed that most Enterobacteriacae 
isolates (41%) produced either high level chromosomal AmpC 
producers or produced plasmid-mediated AmpC CMY-2 
(54.5%). Regarding the strains producing plasmid-mediated 
AmpC, twelve strains (92%) produced AmpC CMY-2 and 
one strain (8%) produced AmpC DHA. These percentages 
are consistent with international ones where the major clus-
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Table 4. MIC determination of the Enterobacteriacae strains against cefotaxime, ceftazidime, cefepime and ertapenem.
Bacterial Strains
MIC on Mueller Hinton agar 
( μg/mL)
MIC on Mueller Hinton agar + Cloxacilline 
(μg/mL)
CT  (1-2) TZ  (1-4)
PM 
(1-4) ETP (0.5-1) CT (1-2) TZ (1-4) PM  (1-4)  ETP (0.5-1)
CMUL E. coli 021 >32.00 >256.00 6.00 0.38 >32.00 8.00 2.00 0.125
CMUL C. braakii 006 1.50 4.00 0.64 0.125 0.125 0.19 0.047 0.032
CMUL E. coli 245 12.00 8.00 0.25 0.064 0.125 0.125 0.023 0.006
CMUL K. pneumoniae 
029 1.00 8.00 0.25 1.00 0.125 0.50 0.19 0.032
CMUL C. freundii 012 >32.00 >256.00 1.00 0.50 3.00 12.00 0.25 0.016
CMUL E. coli 096 2.00 1.00 0.04 0.064 0.047 0.047 0.016 0.008
CMUL E. coli 255 >32.00 64.00 1.50 0.19 0.50 0.75 0.125 0.016
CMUL E. coli 221 >32.00 24.00 0.38 0.19 0.28 0.38 0.032 0.012
CMUL E. cloacae 012 >32.00 64.00 0.50 0.19 3.00 2.00 0.047 0.032
CMUL E. coli 258 >32.00 32.00 0.38 0.064 1.00 2.00 0.125 0.012
CMUL C. freundii 009 >32.00 12.00 0.09 0.19 0.125 0.19 0.016 0.012
CMUL E. coli 226 >32.00 96.00 0.38 0.094 0.75 2.00 0.125 0.016
CMUL E. coli 243 >32.00 64.00 0.38 0.064 0.50 0.75 0.125 0.016
CMUL E. coli 225 24.00 24.00 0.01 0.004 0.023 0.064 <0.016 <0.002
CMUL E. kobei 015 >32.00 16.00 0.12 0.19 0.064 0.064 0.016 0.002
CMUL E. coli 224 6.00 8.00 0.125 0.047 0.032 0.032 <0.016 0.002
CMUL E. cloacae 017 >32.00 64.00 1.00 0.19 0.50 0.38 0.023 0.008
CMUL E. coli 257 >32.00 >256.00 1.00 0.38 1.00 2.00 0.094 0.032
CMUL E. coli 256 >32.00 16.00 0.38 0.125 0.094 0.125 0.023 0.004
CMUL E. cloacae 013 >32.00 4.00 0.094 0.38 0.19 0.125 0.016 0.016
CMUL E. coli 250 >32.00 24.00 0.19 0.064 0.032 0.047 <0.016 0.002
CMUL E. coli 241 >32.00 >256.00 0.50 0.064 0.50 1.50 0.064 0.012
Figure 1.  Chromatogram showing the 
sequence of the promoter of 
the chromosomal AmpC gene.
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ter is the one that gathers the enzymes that are very similar 
to CMY-2. A study conducted in France at Nantes University 
Hospital over 5 years, has showed that all examined E. coli 
strains produced the plasmid-mediated AmpC CMY-2 ( add 
reference ?). Moreover, a study conducted in China [15] and 
designed to determine the prevalence of plasmid-mediated 
AmpC in strains of E. coli and Klebsiella spp., showed that 
among 1935 clinical isolates of E. coli, K. pneumoniae and 
oxytoca, 54 strains (2.79%) produced a plasmid-mediated 
AmpC, 41 strains produced AmpC DHA and 13 strains were 
produced AmpC CMY-2. A similar study conducted in Ja-
pan [16] showed that among 46 strains of k. pneumoniae 
resistant to cephalosporins, only two strains produced the 
plasmid-mediated AmpC CMY-2 and 41 produced the plas-
mid-mediatedAmpC DHA-1.The antibiogram of our strains 
showed that all strains were resistant to cefalotin and cefoxi-
tin, while 86% of the strains were resistant to cefotaxim and 
91% to ceftazidime. However, 86.5% of the strains were 
susceptible to cefepim and only 3 strains were resistant to? 
The determination of MIC showed that 2 strains out of 3 
were not susceptible to cefepim (CMUL E. coli 021 with a 
MIC = 6 μg/mL and CMUL E. coli 255 with a MIC = 1.5 
μg/mL). Sequencing of their chromosomal AmpC encoding 
genes did not show any mutation in the promoter in the -35 
and -10 box or a mutation in the nucleotide at position -42 
(C to T substitution) that are normally responsible for the 
appearance of a strong promoter that causes the high level 
expression of the chromosomal AmpC in E.. coli. Therefore, 
resistance to cefepim in these 2 strains may be due to a mem-
brane impermeability since the 2 strains were also resistant 
to moxalactam which is very sensitive to the membrane im-
permeability [17] and both strains produce plasmid-mediated 
AmpC CMY-2. Susceptibility testing on Mueller-Hinton me-
dium with cloxacillin usimg E-test showed a total recovery of 
susceptible strains to cephalosporins, however, for CMUL E. 
coli 021, there was a partial demonstration of susceptibility 
to cephalosporins on Mueller-Hinton medium with cloxacillin 
and there was no reaction of synergy observed between cla-
vulanic acid/amoxicillin and third-generation cephalosporins. 
Therefore, other beta-lactamase (ESBL) secreted by this strain 
may explain the increase cefotaxime MIC on Mueller Hinton 
with cloxacillin. The synergy reaction was absent on Mueller-
Hinton medium with cloxacillin, but this may be due to the 
outer membrane impermeability since the strain was resis-
tance to moxalactam and it will be difficult to demonstrate 
this synergy in case of impermeability. The molecular typing 
by the ERIC-PCR technique showed the presence of two dis-
tinct clusters. First cluster of two strains and three strains, 
while the other strains each one gave a specific pattern. It 
is highly desirable to conduct further studies using the tech-
nique of pulsed field gel electrophoresis (PFGE) to figure out 
whether the strains within the same cluster were belonged 
actually to the same clone or not. In conclusion, this work 
presents characterization of cephalosporinases produced by 
clinical isolates of Enterobacteriacae in North Lebanon, and 
demonstrates the different plasmid-mediated types of the 
cephalosporinases.
MM: Molecular weight marker, C2: 
CMUL E. coli 258, C3: CMUL E. coli 255, 
C4: CMUL E. coli 226, C5: CMUL E. coli 
021, C6: CMUL E. coli 245, C9: CMUL 
E. coli 225, C10: CMUL E. coli 224, C12: 
CMUL E. coli 257, C13: CMUL E. coli 
256, C14: CMUL E. coli 243, C16: CMUL 
E. coli 250 and C18: CMUL E. coli 241.
Figure 2.  Result of the migration of the 
ERIC-PCR products.
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